Policy

Readmissions are one of the many Achilles' heels of healthcare. Whether it is a failure in communication, problems with medication adherence, or an overall lack of quality healthcare delivery, readmissions cause many headaches within the system. Saturday at the American College of Cardiology 62nd Annual Scientific Session and Expo featured a discussion on successful transitions of care to help prevent readmissions.

A comprehensive presentation of intensity-adjusted hospital price levels and growth rates, including national detail on more than 350 types of hospitalizations, and regional and local averages.

John Glaser, PhD, chief executive officer, Health Services, Siemens Healthcare, says that healthcare is going through a transformation based on payment reform changes.

Patient, clinical, and hospital factors were associated with receiving primary hip arthroplasty versus no surgery after hip fracture in the United States.

Interview With Andrew Pecora, MD, CPE, President, Regional Cancer Care Associates, Chief Innovations Officer and Vice President, Cancer Services, John Theurer Cancer Center at Hackensack University Medical Center

We only have to take a brief look back to see that 10 years ago, most specialty drugs were injectable agents used to treat conditions such as rheumatoid arthritis, multiple sclerosis, and growth disorders. Today, the list of agents that is considered specialty includes many oral drugs and even some inhaled agents. In just more than 2 decades, the specialty drug market place has grown substantially.

The use of oral nutritional supplementation may offer impressive benefits in healthcare resource use and associated costs. Application of evidence-based practice guidelines is recommended.

Across the US, adults with major medical conditions were less likely to die in hospitals with higher spending levels, even after adjusting for patient risk.